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Abstract 
Background: Reports relating to Submandibular gland tumours are sparsely 
reported in the literature. There are some reports of different patterns of tumour types 
in black/negroid patients, as compared to Caucasian patients1,2,11. 
Aim: To provide an audit of the histopathological types and the clinical presentations 
of submandibular gland tumours at our two academic hospitals. 
Method: An analytical cross sectional study using retrospective clinical data 
from in-patient ward registers, patient’s hospital records, operating room/theatre 
registers and the NHLS databases. The study was conducted in the ENT units at the 
Chris Hani Baragwanath Academic Hospital and the Charlotte Maxeke 
Johannesburg Academic Hospital, over a chosen period of 7 years from January 
2005 to December 2011. 
All patients who had a submandibular gland excision by members of the ENT 
department at the two hospitals were included. A total of 61 patient records were 
examined, of which 26 met the inclusion criteria. Data collected included age, 
gender, race and histological diagnosis. 
Data was analysed using standard statistical methods. 
Results: Twenty six patients were included in this study, comprising 46% 
females and 54% males. The ages ranged from 22 to 65 years, with a mean of 42.5 
years – the majority being in the 22-40 years age group. There was no statistical 
difference in the age of males and females (p=0.29), nor in black vs. white patients 
(p=0.29).  
ix 
 
Benign disease was found in 65.4% of patients, while 34.6% had malignancy. Black 
patients had a higher ratio of benign disease than white patients, and black males 
were more likely to have benign disease (83.33%) than black females (50%). 
However, there was no statistical difference in the ratio of benign to malignant 
tumours between blacks and whites. 
Histopathologically, pleomorphic adenoma was the most common benign tumour 
(82%), while adenoid cystic carcinoma was the most common epithelial malignancy 
(22%). There was a high incidence of lymphoma (56% of patients) in the malignant 
group. 
Local pain (p=0.03) and peripheral neurological deficit (p=0.05) was found to be 
significantly associated with malignancy. 
Conclusion: The rate of malignancy in Black patients was found to be lower 
than that reported in the Western literature, which is in keeping with other studies in 
non-Caucasian (Black, Asian and Hispanic) populations1,2,9,11. Additionally, Black 
patients presented at a younger age. Pain and local/peripheral neurological 
involvement were clinical indicators of malignant disease. 
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Chapter 1 - Introduction 
Clinical studies relating to the submandibular salivary gland are less common 
compared to that of the parotid gland. The latter receives more attention due to the fact 
that Parotid gland lesions are far more common, and that surgery of the gland is 
technically more challenging due to the presence of the facial nerve within the gland 
substance, generating more technical interest and study1.  
In Africa, only 3 studies have been done exclusively on submandibular gland 
pathology, and only one of those is from South Africa1,2, describing the spectrum of 
disease found in the submandibular glands. 
1.1 Gross Anatomy 
The human aero-digestive tract comprises 6 major and between 500 to 1000 minor 
salivary glands, scattered throughout the aero-digestive tract. The submandibular 
salivary gland is the second largest salivary gland after the parotid gland, situated in 
the submandibular triangles of the neck. It is bordered by the anterior and posterior 
bellies of the digastric muscle inferiorly and infero-laterally, and the mandible 
superiorly. The submandibular salivary glands are paired structures, approximately 20 
grams each in weight, and each consisting of a superficial or lateral part, and a deep 
part or lobe, which is in anatomical relation to the mylohyoid muscle. Each gland has 
a large single duct, approximately 5cm long, which courses along the floor of the 
mouth to open anteriorly on either side of the lingual frenulum. 
Its arterial supply is from the Lingual branch of the lingual-facial trunk – often the 3rd 
branch of the external carotid artery. Similarly named veins accompany the artery.  
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Secretomotor nerve fibres are conveyed from the facial nerve via the chorda tympani 
nerve, along with the somatic sensory lingual nerve, and synapsing in the 
submandibular ganglion, from which afferent parasympathetic fibres run to the gland 
with the lingual vasculature. Sympathetic fibres accompany the arteries, arising from 
the superior cervical ganglion. Lymphatic drainage is to the upper deep cervical nodes, 
particularly levels I, II and III3,4. 
A number of important peripheral neural structures are noted to lie in close proximity 
to the gland. Of particular importance are the Submandibular Ganglion, the somatic 
sensory lingual nerve, the motor Hypoglossal Nerve and the motor Marginal 
Mandibular Marginal Mandibular Nerve – the second lowest branch of the peripheral 
facial nerve. 
1.2 Micro Anatomy (Histology) 
Salivary glands consist of acini, which are composed of two types of cells: serous or 
mucous. This basic anatomical structure is known as the Salivary Gland Unit (figure 
1). The ratio of these cells differs in each gland; the submandibular gland comprises 
almost equal proportions of each. The ducts consist of cuboidal to columnar 
epithelial cells. Both of these structures are supported by myoepithelial cells, which 
are the innervated contractile structures. The submandibular gland has no 
intraglandular lymph nodes, but lymph nodes are present in the fibrofatty tissue over 
its capsule3. 
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Figure 1 The Salivary Gland Unit (Reproduced with permission from Elluru RG, Lacey J, Rogers J et al. 
Salivary Glands. In: Flint P, Haughey B, Lund V et al, editors. Cummings Otolaryngology Head & Neck 
Surgery. Fifth ed. Philadelphia: Mosby; 2010. p. 1133-1199) 
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Chapter 2 - Literature Review 
2.1 Epidemiology 
The majority of swellings in the submandibular gland are due to mechanical 
obstructions of the duct with consequent inflammation6. Worldwide, salivary gland 
neoplasms are rare, accounting for less than 3% of head and neck neoplasms1,2,5-7. The 
parotid gland is affected most frequently, accounting for 64-80% of cases, followed 
by the submandibular gland, accounting for 7-15% of cases5,7,8. Tumours of the 
submandibular salivary gland account for less than 1% of all head and neck 
neoplasms6. Males and females are equally affected by submandibular gland 
neoplasms, with the peak incidence in the fifth to sixth decades of life6.  
2.2 Clinico-pathology 
Historically, it is believed that the majority (up to 80%) of neoplasms arising in the 
submandibular gland are malignant6-8. However, this figure is based on reports in the 
Western literature. The rates from around the world seem to vary. In Asian and Black 
populations, the incidence of malignancy is as low as 10%2,8,9. 
Spiro reported the largest case series of salivary gland tumours in 1986, at Memorial 
Sloane Kettering Cancer Centre, New York. He reviewed 2807 patients, of which 235 
had neoplasia in the submandibular gland. In his series, 43% of these tumours were 
malignant. Further, most neoplasia occurred in the parotid gland (70%), and only 8% 
in the submandibular gland10. 
In a Ugandan series, Vuhahula (2004) reported a 33% incidence of neoplasia in the 
submandibular gland, and only 22% of those were malignant11. In the only published 
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South African study, Schoeman and Clifford (2007) confirm this low incidence in 
Black patients, with a malignancy rate of 10%2. They analysed 127 patients who had 
resection of salivary gland tumours, of whom 126 were black patients. Of these, 30 
tumours were in the submandibular gland, and only three were malignant. There were 
no white patients with submandibular tumours. Further, similar findings were 
published in Mexican subjects, with 14% malignancy8. A Nigerian study is at odds 
with these findings, and cites a malignancy rate of 52.8%1. 
To date, no reason has been proposed for this heterogeneity in tumour distribution, nor 
for the apparent racial differences6.  Further, there is no study on African Americans, 
reflecting whether the incidence is equally low in that population. 
The commonest benign tumour of the submandibular gland is the Pleomorphic 
Adenoma. Other rare benign tumours include Warthin’s Tumour, oncocytoma and 
lymphoepithelial lesions1,8,10-13. Amongst malignancies, adenoid cystic carcinoma is 
the most commonly reported1,8,11-13. Other histologic types include mucoepidermoid, 
squamous cell carcinoma and carcinoma ex-pleomorphic adenoma. 
The lymphoid tissue of the submandibular gland is considered to be part of Mucosa-
Associated Lymphoid Tissue (MALT), and as such may give rise to lymphoma.1,6,11. 
Further, lymph nodes in the submandibular triangle may be enlarged due to 
lymphoma, without the gland being affected1. 
2.3 Classification 
Salivary gland tumours are classified according to the World Health Organization 
Histological Classification of Salivary Gland Tumours, first published in 1972, and 
revised in 1992 and again in 2005. This allows uniformity, and easy comparison of 
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diagnoses. This classification divides neoplasms into four broad categories, with 
distinct entities in each3,12,14,15 (Table 1). The incidence of particular types depends on 
the site. Polymorphous low-grade adenocarcinoma, for example, almost never affects 
the major glands3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Histological Classification of Tumours of the Salivary Glands. Reproduced with permission from 
Eveson, J.W. 2011, "Salivary tumours", Periodontology 2000, vol. 57, no. 1, pp. 150-159.  
2.4 Clinical Evaluation 
Submandibular tumours most commonly present as a painless mass below the 
mandible, regardless of whether they are benign or malignant1,10,11,13. Pain is a late 
symptom, but should alert to possible malignancy, since it very rarely occurs in benign 
tumours1,5,6,9-11. Patients presenting with advanced disease may present with pain, 
ulceration of the floor of the mouth, regional lymph node enlargement or palsies of 
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the major nerves in the region, namely the marginal mandibular branch of the facial 
nerve, lingual nerve and hypoglossal nerve1,10,11. Tethering of the overlying skin or to 
the mandible is also an indicator of malignancy3. 
History and clinical examination are supplemented by imaging studies, including 
computerised (CT) and magnetic resonance (MRI) tomography. However, radiology 
fails to distinguish between benign and malignant neoplasms, unless there is invasion 
of the surrounding tissues6. Further, there are few studies which evaluate the 
usefulness of CT in submandibular disease9. PET scans are not widely applied to 
salivary tumours, as they are expensive, and do not provide the anatomical detail that 
CT or MRI do3. 
Fine-Needle Aspiration Biopsy (FNAB) is recognised as an accurate technique in the 
diagnosis of salivary gland neoplasms. Sensitivity ranges from 85.5% to 99%, while 
specificity is reported at 96.3% to 100%. However, these ranges are highly operator 
dependant. The most important factor is adequate sampling; this may be improved by 
using ultrasound guidance4,12. Inadequate sampling can result in false-negative rates 
as high as 48%12. 
FNAB is safe and simple to perform4,12. However, its use has been contested, 
particularly whether it would change the management of the patient. In one study, 
FNAB changed the clinical approach in 35% of patients. These changes included 
avoiding surgery for lymphoma, and adopting a more conservative approach for 
benign masses or for high-risk patients. The risk of tumour seeding has been shown to 
be negligible3. The general consensus is that FNAB should be used as an adjunct to 
clinical assessment, but the decision for surgery should be made holistically3,9,12. 
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2.5 Treatment 
Benign tumours are generally treated by surgical excision of the submandibular 
gland. Care should be taken particularly in patients with pleomorphic adenoma, as 
capsule rupture could result in recurrence of the tumour12. Malignant tumours may 
be treated by excision of the gland in early disease. Depending on expertise 
available, some centres undertake excision in regionally advanced disease as well6. 
The decision to do a neck dissection depends on the lymph node status. An in-depth 
discussion on treatment modalities for metastatic disease is beyond the scope of this 
dissertation. 
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Chapter 3 – Materials & Methods 
3.1 Hypothesis 
The rate of submandibular gland malignancy amongst patients at Chris Hani 
Baragwanath and Charlotte Maxeke Johannesburg Academic Hospitals is not as high 
as reported in the Western Literature, in keeping with other studies in Black 
patients1,2,11. 
3.2 Aims and Objectives 
 To audit the histopathology of submandibular gland tumours seen in the 
Department of Otorhinolaryngology at Chris Hani Baragwanath and 
Charlotte Maxeke Johannesburg Academic Hospitals. 
 To describe the clinical presentations of submandibular gland tumours at 
Chris Hani Baragwanath and Charlotte Maxeke Johannesburg Academic 
Hospitals. 
3.3 Study Design 
This study is a retrospective clinical audit.  
3.4 Study Location 
The study was conducted in the clinical units of Otorhinolaryngology at the Chris 
Hani Baragwanath Academic Hospital in Soweto, Johannesburg, and at the Charlotte 
Maxeke Johannesburg Academic Hospital, South Africa. Both hospitals are tertiary 
level teaching hospitals affiliated to the University of the Witwatersrand. 
Page | 10  
 
3.5 Study Period 
The study extended from 1 January 2005 up to 31 December 2011 (7 years).  
3.6 Study Population 
The study included all patients who had submandibular gland surgery with 
subsequent histological analysis.  
3.6.1 Inclusion Criteria 
 All patients with submandibular gland neoplasms, who had been treated 
surgically, and for whom histopathological results were available on the 
NHLS database. 
 Any patient who had only an open biopsy of the submandibular gland 
performed in theatre. 
 Patients must have been attended to by members of the Department of 
Otorhinolaryngology. 
 Patients over 18 years. 
3.6.2 Exclusion Criteria 
 Patients under 18 years of age. The spectrum of salivary gland disease is 
markedly different in children and young adults, in whom inflammatory 
disorders predominate3. They were thus excluded to avoid a selection bias. 
 Patients with non-neoplastic disease. These patients formed part of the initial 
data collection, but were excluded if the histology report showed non-
neoplastic disease. 
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 Patients who had submandibular masses excised that were not part of the 
submandibular gland, and thus did not have a submandibular gland excision. 
 Patients who had needle biopsies performed in the out-patient clinic (difficult 
to trace patient data). 
 Patients who had submandibular resection as part of a neck dissection for 
other Head and Neck malignancies. 
 Patients who had surgery performed by other clinical departments. 
3.7 Data Collection 
Patients were identified from two sources: 
 ENT Operating Theatre register 
 ENT Ward Admissions register 
The operating theatre register was used as a primary reference to identify eligible 
patients. 
The ward admission register was used as a secondary reference to identify patients 
whose theatre record was unclear or lacking detail (eg incorrectly spelt names, 
missing or partial hospital numbers). 
All patients who were clearly identified from the theatre register were recorded as 
part of the initial sample population. This information was then used to interrogate 
the database of the National Health Laboratory Services (NHLS), and all findings 
were recorded into one of the following categories: 
 Histology report, in which a histological analysis was performed on the 
specimen. 
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 No result, in which no result was found on the database. 
 Incomplete or incorrect information, in which insufficient information was 
available to perform the interrogation. 
Patients identified exclusively from the secondary reference were cross checked 
against their recorded laboratory findings and were included in the study population. 
If these patients lacked sufficient information, they were not included in the study 
sample. 
The following data was recorded for each patient (Appendix A): 
 Hospital registration number 
 Age 
 Sex 
 Race 
 Presenting complaint 
 Clinical findings 
 Date of surgery 
 Histological result 
All data was recorded electronically using Microsoft Access and Microsoft Excel. 
3.8 Data Analysis and Presentation 
The following software was used for data manipulation, analysis and presentation: 
 Microsoft Access 2013 for data storage, retrieval and selection. 
 Microsoft Excel 2013 for descriptive analysis, summary statistics and 
comparison of sample means. 
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 Standard statistical methods were used. Student’s t test was used to analyse 
continuous data and the Chi Square (X2) test for ordinal data. Fischer’s Exact 
Test was used for ordinal data where actual counts were less than five. A 
probability (p) value of less than (or equal to) 0.05 was regarded as 
significant. 
 Microsoft Word 2013 for final documentation and presentation. 
3.9 Ethics Committee Approval 
As this is a retrospective clinical audit, no patient consent was required.  The study 
was approved by the Human Research Ethics Committee of the University of the 
Witwatersrand (Clearance Number M120286 – Appendix B).  
Signed written approvals were obtained from the CEO’s of the respective hospitals, 
as well as the Head of the Department of Anatomical Pathology, to access histology 
results (Appendix C). 
All data was confidential and stored on a password-protected database, to which the 
principle researcher alone had access. 
3.10  Funding 
No funding was required for this study. The minimal costs incurred were covered by 
the University of the Witwatersrand’s Department of Otorhinolaryngology study 
budget, or personally financed. 
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3.11  Potential Limitations 
 Cross-sectional study 
 Inadequate records 
 Inadequate patient numbers 
 Not all patients with submandibular disease will be accounted for, since not 
all have excision as part of their management. Also, not all patients are 
attended to by members of the Department of Otorhinolaryngology (some are 
seen by members of General Surgery, for example). This could cause a 
selection bias. 
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Chapter 4 – Results 
4.1 Study Sample 
A total of 61 patients were identified who had had submandibular gland excision. Of 
these, 29 patients were excluded because they had non-neoplastic disease, three 
patients were excluded because they were younger than 18 years of age, and 3 were 
excluded because there were no histological results available. Thus, a total of 26 
patients were included in the study sample 
4.2 Demographic data  
4.2.1 Age 
The age ranged from 22 to 65 years, with a mean age (SD) at surgery of 42.5 years 
(14.5). The majority (53.85%, n=14) of patients were aged 21-40 years. Of these, 
30.8% (n=8) were male and 23.1%% (n=6) were female. Although the average male 
age was 45.3 and females were 39.2, a t-test revealed no significant difference in the 
age of males and females (p=0.29). Furthermore, the mean age of black patients 
(40.78 year) was not significantly different from that of white patients (51.75 years), 
p=0.29. Additionally, there was no significant difference between the mean age of 
patients with benign (40.29 years) versus malignant disease (46.56 years), p=0.29. 
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Figure 2 Age distribution 
4.2.2 Gender 
Females represent 46% (n=12) and males 54% (n=14) of the sample. The 
male:female ratio is thus 1.17:1. 
 
Figure 3 Gender distribution 
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4.2.3 Race 
Twenty-two patients (84.6%) were black; the remainder (n=6) were white. No other 
racial denominations were represented. Of the black patients, 12 were male, 
representing 54.6%, and 10 were female (45.4%). Among white patients, 2 patients 
were male, and 2 female, representing 50% each. 
 
Figure 4 Racial distribution 
4.2.4 Distribution across hospitals 
Most patients were found at CMJAH, representing 62% (n=16). The remainder were 
at CHBH (38%, n=10). 
 
Figure 5 Distribution across hospitals 
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4.2.5 Distribution over time 
There was no significant difference in the number of patients presenting in different 
years. On average, 3.7 patients per year were operated on for neoplasia, ranging from 
2 to 5 per year. 
 
Figure 6 Distribution over time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Summary - Demographics by gender 
 
Variables  Males  Females 
    
Age Groups     
<20  0  0 
20‐40  8 (30.8%)  6 (23.1%) 
41‐60  2 (7.7%)  5 (19.2%) 
>60  4 (15.4%)  1(3.8%) 
Hospitals     
CMJAH  6 (23.1%)  10 (38.5%) 
CHBH  8 (30.8%)  2 (7.7%) 
Yearly Statistics     
2005  0  3 (25.0%) 
2006  1 (7.1%)  3 (25.0%) 
2007  2 (14.3%)  0 
2008  1 (7.1%)  3 (25.0%) 
2009  4 (28.6%)  1 (8.3%) 
2010  4 (28.6%)  0 
2011  2 (14.3%)  2 (16.7%) 
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4.2.6 Histologic characteristics 
In total, 17 patients had benign disease, representing 65.4%, while the remaining 9 
patients (34.6%) had malignant disease. 
Out of the total of 17 patients with benign tumours, benign disease was present in 15 
black patients (88.2%), and 2 white patients (11.8%). Proportionally, this represents 
68.18% of black patients (n=15) and 50% of white patients (n=2). In black patients, 
10 were male and 5 were female. White patients were represented equally across 
gender (1 male and 1 female). Thus, in total, 6 females (50% of total number of 
females) and 11 males (78.57% of total number of males) had benign disease.  
In patients with malignant disease, 7 were black (77.8%), while 2 were white 
(22.2%). Proportionally, blacks with malignant disease account for 31.8% (n=7), and 
whites 50% (n=2). Of the 7 black patients, 2 were male and 5 were female. In white 
patients, again there was 1 male and 1 female. In total, 3 males (21.43% of total 
number of males) and 6 females (50% of total number of females) had malignant 
disease.  
 
Figure 7 Histologic distribution 
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Figure 8 Histologic distribution by gender 
 
Figure 9 Histologic distribution by race 
Comparing the ratio of benign to malignant tumours between blacks and whites, 
revealed no statistical significance when using Fisher’s Exact test (p=0.59). 
 
Figure 10 Proportional histology by race 
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4.2.6.1 Distribution	of	benign	tumours	
Of the total of 17 benign tumours, the majority (82.4%) were pleomorphic 
adenomas. The other 3 were lipomas. No other histological types were encountered. 
 
Figure 11 Benign tumours 
4.2.6.2 Distribution	of	malignant	tumours	
Lymphomas were the most commonly found malignant tumours (55.6%). The most 
common epithelial tumour was Adenoid Cystic carcinoma (22.2%). There was one 
each of Squamous Cell carcinoma and Carcinoma ex Pleomorph. No other 
histological types were found. 
 
Figure 12 Malignant tumours 
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4.2.7 Clinical signs and symptoms 
4.2.7.1 Pain	
Pain was the presenting feature in 7 patients (27%). Of those, only 2 had benign 
disease; the remainder had malignancies. This difference was found to be statistically 
significant, using Fisher’s exact test (p=0.03) 
 
Figure 13 Pain as a presenting feature 
4.2.7.2 Tenderness	
Only 3 patients (12%) had tumours which were tender on palpation; 1 had benign 
disease and 2 had malignant disease. Tenderness was not found to be statistically 
associated with malignancy (p=0.27). 
 
Figure 14 Incidence of tenderness 
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4.2.7.3 Marginal	Mandibular	Nerve	weakness	
Only 3 patients had clinically obvious marginal mandibular nerve weakness 
(evidenced by drooping of the corner of the mouth), but all had malignant disease. 
However, this was found to be statistically significant (p=0.05). 
 
Figure 15 Marginal mandibular nerve palsy 
4.2.7.4 Other	clinical	signs	&	symptoms	
No patients had hypoglossal nerve palsies (indicated by weakness of the tongue), 
skin tethering, fixation to the mandible or ulceration of the skin. 
Clinical signs n % 
Pain   
Absent 19 73.1 
Present 7 26.9 
Tenderness   
Absent 23 88.5 
Present 3 11.5 
Marginal mandibular weakness   
Absent 23 88.5 
Present 3 11.5 
 
Table 3 Summary of clinical signs 
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Marginal Mandibular Palsy
Drooping
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Signs Benign Malignant P value
No pain 15 4 0.03 
Pain 2 5  
No facial weakness 17 6 0.05 
Facial weakness 0 3  
No tenderness 16 7 0.27 
Tenderness 1 2  
 
Table 4 Difference between benign & malignant tumours wrt clinical signs  
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Chapter 5 – Discussion 
The aim of this project was two-fold: 
1. To audit the clinicopathology of submandibular gland tumours 
2. To assess whether the malignancy rate in a South Africa population is 
comparable to results elsewhere in Africa. 
5.1 Limitations 
It is of note that this is a retrospective data collection based on a defined set of 
criteria. The data was obtained from old – not so well kept – patient records, the 
consistency and quality of which varied considerably. 
The study was conducted at two of the largest academic hospitals in South Africa, 
namely Chris Hani Baragwanath Hospital, and Charlotte Maxeke Johannesburg 
Academic Hospital. Patient numbers in these two hospitals are enormous, and 
accessing records proved challenging. 
In addition, submandibular gland tumours are not common6. Thus, obtaining 
statistically significant patient numbers for study was challenging. Nonetheless, the 
data presented compares favourably with other studies in terms of sample size1,5,6,8. 
Due to this small sample size, however, conclusive analysis is not possible. 
Another limitation in collection of data was that only records from the Department of 
Otorhinolaryngology were accessed. Submandibular tumours are, however, also 
attended to by other disciplines, most notably Maxillofacial and General Surgery. 
Additionally, not all patients with tumours have a surgical excision as treatment. 
Therefore, the true incidence may not be reflected in this study. 
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Lastly, this study was only conducted at two hospitals, serving a very similar 
population group. The results may not extend to other populations or regions. 
5.2 Demographic Data 
Although there were no statistical significance in the demographic data reviewed, it 
is worthwhile to compare our findings to those of other studies. 
5.2.1 Age 
The mean age of patients presenting with any submandibular tumour was 42.5 years. 
This compares well with other studies in Africa, which show a similar trend1,2,11. A 
study amongst Asian patients also showed similar findings9. However, in Western 
literature, the mean age is markedly higher6-8,10. 
Most tumours occurred in the age group 22 – 40 years. This contrasts markedly with 
the international literature which quotes a peak incidence at 40 – 60 years10,12. 
The data therefore suggests that submandibular tumours occur at younger ages in 
non-Caucasian races. 
There was no difference in the mean ages of males vs. females, nor of patients with 
benign vs. malignant disease. Our findings concur with that of the Pretoria study2. 
5.2.2 Sex 
Overall, males and females were almost equally represented, with a ratio of 1:1.17. 
This is in keeping with some studies, which show no difference in the ratio of males 
to females1,2,6,12. However, other studies have shown a higher incidence in 
females8,11, as high as 3:1 in one study5. It should be noted that certain tumour types, 
particularly Warthin’s Tumour, have a marked sex predilection, although none of our 
patients presented with this entity. 
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Analysis of the data gathered, especially with regards to the ratio of males to females 
and with regard to tumour behaviour i.e. benign vs. malignant in different race 
groups, revealed that, in black patients, males were more likely to have benign 
disease than females, with a ratio of 2:1. The incidence of malignant disease was 
higher in females in the ratio 2.5:1. These findings are comparable with other 
studies5,8. 
5.2.3 Race 
There are no studies which specifically examine differences between races. In our 
study, the majority of patients were black patients. Due to the limited number of 
patients, no further statistical analysis was possible in terms of clinical presentation 
or tumour types. However, there was no statistical difference in the ages of black 
compared to white patients. 
5.2.4 Presenting Hospital 
Most patients presented at CMJAH. The reasons for this are not clear, but may 
include better primary facility referral, and patient education.  
There was also no difference in the number of patients from year to year, over the 
time period under study. 
5.3 Histologic characteristics 
Of the total of 26 patients, 17 patients (65.4%) had benign tumours, and 9 (34.5%) 
had malignant tumours. Overall, this is a striking contrast to the commonly quoted 
rates of malignancy in the general literature, of up to 80%1,6,10,12. When account is 
taken of race, this increases to 68.2% of black patients having benign disease. 
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Interestingly, although there were only 4 white patients, the ratio follows that of 
Western literature (50% malignancy). 
Other African studies have also found that the rate of malignancy is markedly lower 
in black patients2,11. 
The difference in malignancy rate between blacks and whites was not found to be 
statistically significant, however. 
5.3.1 Benign tumours 
The majority of benign tumours were pleomorphic adenomas. This is consistent with 
all studies, both African and western1,2,5,8,11. No other histological subtypes were 
found. This is probably due to the low number of patients in the study, but the rarity 
of Warthin’s tumour in black patients has been noted previously11. 
Three patients had lipomas. Although primary lipoma of the submandibular gland 
has been described16, it is exceedingly rare. It is more likely that these patients had a 
lipoma of the peri-glandular soft tissues, which is abundant in fat, which was excised 
together with the gland.  
5.3.2 Malignant tumours 
The dominant malignant disease / tumour – found mostly in females – was the 
Lymphoma. Lymphomas commonly occur in the lymphatic tissues surrounding the 
gland, but have also been described as primarily involving the submandibular 
gland17.  
The commonest epithelial malignancy encountered was adenoid cystic carcinoma. 
Several other studies have shown this trend1,5,6,13. However, Becerill-Ramírez et al 
reported adenocarcinoma and squamous cell carcinoma as the most common. They 
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do, however, acknowledge that a limitation of that study was very low patient 
numbers (22 patients over 10 years)8. Studies in Africa have shown a similar 
pattern2,11. 
5.4 Clinical signs and symptoms 
5.4.1 Pain and tenderness 
Most patients did not present complaining of pain. However, when pain was present, 
it was strongly associated with malignant tumours. Most studies confirm that the 
presence of pain is a sinister feature1,10,12,13,18. 
Tenderness was present in only 3 patients. We did not find a significant difference 
between benign and malignant tumours, although most reports indicate that 
tenderness is often associated with malignancy. 
5.4.2 Neurological sequaelae 
Weakness of the marginal mandibular nerve was present in 3 patients, all of whom 
had malignant disease. Thus, neurological involvement is a strong indicator of 
malignancy. This is in keeping with other studies1,6,13. 
Although none of our patients presented with it, weakness of the hypoglossal and 
lingual nerves has also been reported6,12,13. 
5.4.3 Other symptoms 
Fixation to skin or the mandible, and ulceration of the skin has been reported as 
indicating malignancy1. No patients in our series had these features. 
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5.5 Summary 
The data presented in this study confirms our hypothesis, that black patients have a 
lower rate of submandibular gland malignancy than is reported in the literature. This 
is in keeping with other studies in Africa. 
Furthermore, tumours in black patients tend to occur in lower age groups. This is 
particularly true of malignant tumours. 
Pleomorphic adenoma and adenoid cystic carcinoma were the commonest epithelial 
benign and malignant tumours, respectively.  
Pain and neurological weakness were confirmed as being associated with malignant 
tumours 
5.6 Suggested research & recommendations 
We did not examine the HIV status of the patients involved in this report. The reason 
for this was that in most cases the data was not available, and patients could not be 
contacted to give informed consent for testing. 
In view of the high number of lymphomas that were presented, it would make sense 
to test the association of submandibular malignancy with HIV, since the latter is 
known to cause lymphoma, and is potentially oncogenic. 
Although the number of patients we examined was limited, in view of other studies 
of a similar nature, we would recommend a higher index of suspicion in young black 
patients presenting with submandibular masses. 
Lastly, a prospective, multicentre study with larger samples should be conducted to 
confirm our and other studies’ findings. 
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Appendix A 
Study Number  
Age <20 
 21-40 
 41-60 
 >60 
  
Gender Male 
 Female 
  
Race Black 
 White 
  
Clinical signs and 
symptoms 
Swelling 
 Drooping of the mouth 
 Tongue weakness 
 Tenderness 
 Pain 
 Skin ulceration 
 Tethering to mandible or skin 
  
Histological type  
Benign Pleomorphic adenoma 
 Warthin’s tumour 
 Oncocytoma 
 Myoepithelial adenoma 
 Basal cell adenoma 
 Other (Specify) 
Malignant Muco-epidermoid carcinoma 
 Adenoid cystic carcinoma 
 Adenocarcinoma 
 Epidermoid carcinoma 
 Myoepithelial carcinoma 
 Squamous cell carcinoma 
 Lymphoma 
 Other (Specify) 
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Appendix B 
Ethics clearance certificate 
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5. Head of Department of Anatomical Pathology – National Health Laboratory 
Service, University of the Witwatersrand 
 


  
 
CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC HOSPITAL 
 
Office of the CEO 
Enquiries:  
Ms. L. Mngomezulu 
(011): 488-3793 
(011)  488-3753 
29th January 2013 
 
Dr. Yahya Atiya  
Division of Otorhinolaryngology  
CMJAH 
 
Dear Dr. Atiya               
 
RE:  “Submandibular gland tumours: A clinic-pathological review at the Charlotte Maxeke 
Johannesburg Academic Hospital” 
 
Permission is granted for you to conduct the above research as described in your request provided:  
  
1. Charlotte Maxeke Johannesburg Academic hospital will not in anyway incur or inherit costs as a 
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